stomach issues on tirzepatide (Mounjaro) The promise of tirzepatide: A

The FDA Zepbound label reports hair loss more often in women than men, 7.1% vs 0.5%, and explicitly notes the reaction was associated with weight reduction in trial participants

oral: We prefer injections better absorption, better results

Trimethylamine plasma levels increased proportionately with L-carnitine dose, but there was no change in renal clearance

Sources FDA Prescribing Information: Zepbound (tirzepatide) January 2026 label New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) AJMC: FDA Approves Monthly KwikPen Option for Tirzepatide Drugs.com: Tirzepatide (Zepbound) dosing and safety Eli Lilly: Mounjaro Prescribing Information Medical disclaimer This article is for educational purposes only and does not constitute medical advice

Check the label for storage instructions, as some probiotics are shelf-stable while others need refrigeration

Prescription from a healthcare provider for Zepbound as part of a comprehensive treatment plan